| dc.date.accessioned | 2022-02-23T08:54:53Z | |
| dc.date.available | 2022-02-23T08:54:53Z | |
| dc.date.issued | 2022 | |
| dc.identifier.uri | http://hdl.handle.net/10852/91402 | |
| dc.description.abstract | Antibody radionuclide conjugate therapy is a treatment modality that utilizes monoclonal antibodies linked to radionuclides. [177Lu]Lu-lilotomab satetraxetan is a novel therapy targeting the CD37-antigen currently in a first-in-man clinical trial treating patients with indolent non-Hodgkins lymphoma. In addition to tumoricidal beta-radiation, 177Lu also emits gamma-radiation that can be detected by a SPECT-scanner.
In our work we have used SPECT/CT-images of patients treated with [177Lu]Lu-lilotomab satetraxetan acquired at multiple time points after therapy. These were used to quantify the absorbed dose to tumors as well as normal organs.
Our main findings indicate that the main organ at risk is the red marrow, and that myelosuppression correlated with the absorbed dose, which can hence be used to predict this toxicity. Furthermore, different treatment arms with and without pre-dosing with unlabeled lilotomab were included in the LYMRIT-37-01-trial, and we found that pre-dosing with unlabeled lilotomab results in a favorable biodistribution. | en_US |
| dc.language.iso | en | en_US |
| dc.relation.haspart | Paper I. J. Blakkisrud, JE. Holtedahl A. Løndalen, J. Dahle, T. Bach-Gansmo, H. Holte, S. Nygaard, A. Kolstad and C. Stokke. "Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177 Lu-Lilotomab Satetraxetan". In: Journal of Nuclear Medicine 59 (2018), pp. 704–710. DOI: 10.2967/jnumed.117.195347. The article is not available in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.2967/jnumed.117.195347 | |
| dc.relation.haspart | Paper II. J. Blakkisrud, A. Løndalen, J. Dahle, S. Turner, H. Holte, A. Kolstad and C. Stokke. "Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate". In: Journal of Nuclear Medicine 58 (2017), pp. 55–61. DOI: 10.2967/jnumed.116.180471. The article is not available in DUO due to publisher restrictions. The published version is available at: https://doi.org/10.2967/jnumed.116.180471 | |
| dc.relation.haspart | Paper III. C. Stokke, J. Blakkisrud, A. Løndalen, J. Dahle, ACT. Martinsen, H. Holte and A. Kolstad "Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients". In: European Journal of Nuclear Medicine and Molecular Imaging 45 (2018), pp. 1233–1241. DOI: 10.1007/s00259-018-3964-9. The article is included in the thesis. Also available at: https://doi.org/10.1007/s00259-018-3964-9 | |
| dc.relation.haspart | Paper IV. J. Blakkisrud, A. Løndalen, J. Dahle, ACT. Martinsen, A. Kolstad and C. Stokke "Myelosuppression in Patients Treated with 177-Lutetium-Lilotomab Satetraxetan can be Predicted with Absorbed Dose to the Red Marrow as the Only Variable". In: Acta Oncologica 60 (2021) pp. 1481–1488. DOI: 10.1080/0284186X.2021.1959635. The article is included in the thesis. Also available at: https://doi.org/10.1080/0284186X.2021.1959635 | |
| dc.relation.uri | https://doi.org/10.2967/jnumed.117.195347 | |
| dc.relation.uri | https://doi.org/10.2967/jnumed.116.180471 | |
| dc.relation.uri | https://doi.org/10.1007/s00259-018-3964-9 | |
| dc.relation.uri | https://doi.org/10.1080/0284186X.2021.1959635 | |
| dc.title | Dosimetry in patients treated with [177Lu]Lu-lilotomab satetraxetan | en_US |
| dc.type | Doctoral thesis | en_US |
| dc.creator.author | Blakkisrud, Johan | |
| dc.identifier.urn | URN:NBN:no-93990 | |
| dc.type.document | Doktoravhandling | en_US |
| dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/91402/1/PhD-Blakkisrud-2022.pdf | |